WO1994009750A1 - Cosmetic composition - Google Patents

Cosmetic composition Download PDF

Info

Publication number
WO1994009750A1
WO1994009750A1 PCT/GB1993/002210 GB9302210W WO9409750A1 WO 1994009750 A1 WO1994009750 A1 WO 1994009750A1 GB 9302210 W GB9302210 W GB 9302210W WO 9409750 A1 WO9409750 A1 WO 9409750A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
metabolic intermediate
derivatives
hair
composition
Prior art date
Application number
PCT/GB1993/002210
Other languages
French (fr)
Inventor
Walter Thomas Gibson
George Terence Evelyn Kealey
Gillian Elizabeth Westgate
Original Assignee
Unilever Plc
Unilever N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc, Unilever N.V. filed Critical Unilever Plc
Priority to CA002146348A priority Critical patent/CA2146348A1/en
Priority to AU53426/94A priority patent/AU5342694A/en
Priority to JP6510821A priority patent/JPH08502509A/en
Priority to EP93923626A priority patent/EP0666729A1/en
Publication of WO1994009750A1 publication Critical patent/WO1994009750A1/en
Priority to KR1019950701705A priority patent/KR950703926A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof

Definitions

  • the invention relates to a cosmetic composition for topical application to mammalian skin or hair for increasing or at least maintaining hair growth, especially terminal hair growth on the human scalp.
  • the hair growth cycle can be divided into three main stages, namely: i) an active stage known as anagen, during which the hair follicle penetrates deep into the dermis with the cells of the bulb dividing rapidly and differentiating to form the hair, ii) a regressive stage known as catagen, which is heralded by the cessation of mitosis, and during which the follicle regresses upwards through the dermis and hair growth ceases, and iii) a resting stage known as telogen, in which the regressed follicle contains a small secondary germ with an underlying ball of tightly packed dermal papilla cells.
  • an active stage known as anagen
  • catagen which is heralded by the cessation of mitosis, and during which the follicle regresses upwards through the dermis and hair growth ceases
  • telogen a resting stage known as telogen
  • citrulline which condenses with aspartate to form argininosuccinate, may also regulate the steps of arginine/urea synthesis by its availability, which would depend on oxaloacetate and in turn TCA cycle intermediates.
  • the availability of arginine may also be important for
  • RNA and protein biosynthesis due to its being an essential amino acid.
  • the significance of ornithine may be due to its role in the generation of arginine in the follicle rather than to urea. In the process, fumarate is produced which can feed into the TCA cycle and contribute to anaplerotic reactions. Without ornithine and arginine, the ammonia which results from a surplus of nitrogen caused by glutaminolysis may rise to toxic levels and prove fatal to cell function due its inhibition of transaminase reactions and hyperglutaminaemia.
  • supplementing a composition intended for topical application with metabolic intermediates of the urea cycle can cause an increase in hair growth in excess of that previously observed for glutamine.
  • the invention is accordingly concerned with the use of these intermediates in hair follicle metabolism, so as to increase or maintain hair growth.
  • the invention provides a composition which is suitable for topical application to mammalian skin or hair for increasing, enhancing or maintaining hair growth, which composition comprises:
  • an effective amount of a metabolic intermediate of the urea cycle chosen from arginine, ornithine, citrulline, argininosuccinate, their salts, hydrosalts and precursors thereof, and mixtures thereof; and
  • the invention provides a method of increasing, enhancing or maintaining hair growth by use of such a composition. Use is by topical application
  • the invention is concerned with the utilisation of a metabolic intermediate which is part of the urea cycle, or a derivative of such a metabolic intermediate, and its topical application for the purposes of increasing or maintaining hair growth, particularly on the human scalp.
  • urea cycle and its involvement in glutaminolysis (so important in hair growth) via the tricarboxylic acid (TCA) cycle is shown in Figure 1. From this, four metabolic intermediates of the urea cycle, namely arginine, ornithine, citrulline and argininosuccinate have been selected as possessing the ability to promote linear hair growth to an extent which is significantly greater than glutamine itself.
  • Each of these four metabolic intermediates can therefore incorporated into a composition for topical application to skin or hair, in particular the scalp, for promoting or at least maintaining hair growth.
  • a particularly preferred example of a salt is the sodium salt, and a preferred example of a hydro salt is a
  • hydrohalide especially the hyrochloride derivatives of these intermediates. It is further possible to employ other derivatives including acyl, ester and peptide derivatives of these metabolic intermediates. These too may be used as salts or hydrosalts.
  • R 1 is chosen from: (i) H-,
  • peptide residues comprising from 2 to 8 amino acid residues or substituted amino acid residues, which are substituted as defined in (iv) above; the amino acid residues or substituted amino acid residues, as herein defined, being derived from one or more of the following amino acids:
  • DOPA L-3,4-dihydroxyphenylalanine
  • alkali metal cations chosen from Na + and K + , (i ⁇ ) NH 4 + or alkanolammonium ions, and
  • hydrohalide derivatives of urea cycle intermediates are: arginine hydrochloride (10)
  • alkali metal salt derivatives of urea cycle intermediates are: sodium arginate (12)
  • dipeptide derivatives of urea cycle intermediates are:
  • Preferred examples of other derivatives of urea cycle intermediates are: methylarginine dihydrochloride (32)
  • composition can comprise two or more urea cycle intermediates or derivatives thereof, as herein defined.
  • the chosen urea cycle intermediate is citrulline, or a derivative thereof
  • it is preferably to include aspartate in the composition according to the invention, in view of the combination of citrulline and aspartate to from arginosuccinate, as is evident from Figure 1.
  • the chosen urea cycle intermediate is ornithine, or a derivative thereof
  • carbamoyl phosphate in the composition accordingly to the invention, as carbamoyl phosphate promotes the formulation of citrulline from ornithine, as can also be seen from Figure 1.
  • the total amount of the urea cycle intermediate or derivative thereof present in the composition according to the invention is an amount which is sufficient to induce maintain or increase hair growth.
  • This amount will depend on the effectiveness of the intermediate, some being more effective than others, but in general an amount of from 0.001 to 99%, usually from 0.01 to 30% by weight of the composition will provide an adequate concentration for application to the skin, particularly the scalp, which can then be repeated as necessary to promote hair growth.
  • composition according to the invention also comprises a solid, semi-solid or liquid cosmetically and/or physiologically acceptable vehicle, to enable the urea cycle intermediate, or derivative thereof, to be conveyed to the skin at an appropriate dilution.
  • vehicle will depend upon the method chosen for topical administration of the composition.
  • the vehicle can itself be inert or it can possess physiological or pharmaceutical benefits of its own.
  • a vehicle for this purpose presents a wide range of possibilities depending on the required product form of the composition. Suitable vehicles can be classified as described hereinafter.
  • vehicles are substances which can act as diluents, dispersants, or solvents for the urea cycle intermediate, or derivative thereof, which therefore ensure that they can be applied to and distributed evenly over the hair and/or scalp at an appropriate concentration.
  • the vehicle is preferably one which can aid penetration of the esters into the skin to reach the immediate environment of the hair follicle, compositions according to the invention can include water as a vehicle, and/or at least one cosmetically acceptable vehicle other than water.
  • Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
  • Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil,
  • Propellants such as propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide
  • Solvents such as ethyl alcohol., methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxid ⁇ , dimethyl formamide, tetrahydrofuran;
  • Powders such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, ethylene glycol distearate;
  • the cosmetically acceptable vehicle will usually form from 10 to 99.999%, preferably from 10 to 99% and most preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
  • composition according to the invention can also optionally comprise an activity enhancer.
  • the activity enhancer can be chosen from a wide variety of molecules which can function in different ways to enhance the hair growth effects of the urea cycle intermediate.
  • Particular classes of activity enhancers include (a) other hair growth stimulants, (b) penetration enhancers and (c) cationic polymers, whose presence can further improve the delivery of the ester through the stratum corneum to its site of action in the immediate environment of the hair follicle.
  • Some activity enhancers can also function as vehicles for the ester.
  • Other Hair Growth Stimulants i. Examples of other substances which themselves possess the ability to stimulate or increase hair growth include, for example:
  • Unilever in EP 0 277 428 such as N- acetylglucosamine.
  • Glycosaminoglycan chain cellular uptake inhibitors as described by Unilever in EP 0 277 428, such as hexuronic acid and esters thereof.
  • Chemical inhibitors of glycosidase activity as described by Unilever in EP 0 334 586, chosen from lactams, such as D-glucaro-1,5-lactam.
  • Chemical activators of protein kinase C enzymes as described by Unilever in EP 0 334 585 chosen from diacylglycerols, such as 1,2-Dioleoyl-sn- glycerol.
  • Unilever in EP 0 348 184 chosen from acylated monosaccharides, such as 2-propionamido-2- deoxyglucose. xv. Esters of pyroglutamic acid, as described by
  • a penetration enhancer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery through the stratum corneum to its site of action in the hair follicle.
  • the penetration enhancer can accordingly function in a variety of ways. It can for example, improve the distribution of the urea cycle intermediate on the skin surface or, it can increase its partition into the skin from the composition when applied topically, so aiding its passage to its site of action. Other mechanisms enhancing the benefit of the hair growth promoter may also be involved.
  • penetration enhancers examples include:
  • a cationic polymer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery to the hair and scalp.
  • preferred cationic polymers include:
  • Quaternised poly (dimethylaminoethylmethacrylate); and mixtures thereof
  • the amount of activity enhancer when employed in accordance with the invention, will normally be from 0.1 to 50%, preferably from 0.5 to 25% and most preferably from 0.5 to 10% by weight of the composition.
  • composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.
  • HLB hydrophilic-lyophilic balance
  • composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
  • oils examples include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients.
  • oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.
  • the oil or oily material when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
  • Emulsifiers can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed.
  • the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6.
  • a chosen emulsifier or emulsifiers should have an average HLB value of >6.
  • Suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
  • Sorbitan trioleate Arlacel 85 1.8 Sorbitan tristearate Span 65 2.1 Glycerol monooleate Aldo MD 2.7 Glycerol monostearate Atmul 84S 2.8 Glycerol monolaurate Aldo MC 3.3 Sorbitan sesquioleate Arlacel 83 3.7 Sorbitan monooleate Arlacel 80 4.3 Sorbitan monostearate Span 60 4.7 Poloxyethylene (2)
  • the amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
  • composition of the invention can also comprise water, usually up to 90%, preferably from 5 to 80% by volume. Water can function as the cosmetically acceptable vehicle.
  • composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
  • the silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight from 10,000 to 50,000.
  • the dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane.
  • the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
  • volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).
  • a particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C
  • Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
  • the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
  • composition for use in the method according to the invention can be formulated as a shampoo and will then accordingly comprise one or more surfactants which are cosmetically acceptable and suitable for topical
  • composition of the invention can comprise an anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl sulphosuccinate, dialkylsulphosuccinate, acryl lactylate, acylated ⁇ -amino acid, alkyl carboxylate, monoalkyl phosphate and dialkyl phosphate.
  • anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl s
  • anionic surfactants include: alkyl sulphates, such as sodium lauryl sulphate [eg.
  • alkylether sulphates such as sodium lauryl ether sulphate
  • alkyl sulphonates such as sodium alkane (C 13-18 ) sulphonate [eg. HOSTAPUR SAS 30, available from Hoechst].
  • alkylaryl sulphonates such as sodium alkyl benzene sulphonate [eg. TEEPOL CM44, available from Shell].
  • olefin sulphonates such as sodium olefin sulphonate (C 5-18 ) [eg. HOSTAPUR OS, available from Hoechst].
  • acyl sarcosinates having the structure: (51)
  • R 3 is chosen from C 6-14 alkyl
  • M is a counterion chosen from alkali metals, ammonium and substituted ammonium such as alkanolammonium.
  • acyl sarcosinate having the structure (51) is sodium lauryl sarcosinate [eg. HAMPOSYL L-95, available from Grace] .
  • R 4 is chosen from C 8-18 alkyl
  • acyl tauride having the structure (52) is coconut methyl taurine [eg. FENOPEN TC 42, available from GAF].
  • acyl isethionates having the structure ( 53 ) :
  • R 5 is chosen from C 8-18 alkyl.
  • An example of an acyl isethionate having the structure (53) is sodium acyl isethionate [eg. JORDAPON Cl, available from Jordon].
  • monoalkyl sulphosuccinates, having the structure (54) is sodium acyl isethionate [eg. JORDAPON Cl, available from Jordon].
  • R 6 is chosen from C 10-20 alkyl.
  • Examples of monoalkyl sulphosuccinates having the structure (54) include: sodium lauryl sulphosuccinate [eg. EMPICOL SLL, available from Albright & Wilson]. magnesium alkyl sulphosuccinate [eg. ELFANOL 616 Mg, available from AKZO]. sodium lauryl ethoxysulphosuccmate [eg. EMPICOL SDD, available from Albright & Wilson]. coconut monoethanolamide ethoxysulphosuccmate [eg. EMPICOL SGG]. disodium lauryl polyglycolether sulphosuccinate [eg. SURTAGENE S30, available from CHEM-Y]. polyethyleneglycol sulphosuccinate [eg. REWOPOL SBFA 30, available from REWO]. dialkyl sulphosuccinates, having the structure (55):
  • R 7 and R 8 are the same or different, and are chosen from C 6-14 alkyl.
  • a dialkyl sulphosuccinate having the structure (55) is sodium dilauryl sulphosuccinate [eg. EMCOL 4500, available from Witco].
  • R 9 is chosen from C 6-16 alkyl, and n is 1 or 2.
  • acyl lactylate having the structure (6) is decanoyl lactylate [eg. PATIONIC 122a, available from Patterson, CJ].
  • acylated a-amino acids such as sodium lauroyl glutamate [eg. ACYLGLUTAMATE LS-11, available from Ajinomoto Co. Inc].
  • ethyl carboxlates such as alkyl C 12-14 O(EO) 4 OCH 2 CO 2 Na [eg. AKYPO RLM 38, available from Akzo].
  • monoalkyl phosphates such as monolauryl phosphate, and dialkyl phosphates. such as dioctyl phosphate.
  • the shampoo compositions of the invention also comprise amphoteric surfactant.
  • Suitable amphoteric surfactants are derivatives of aliphatic quaternary ammonium, phosphonium and sulphonium ⁇ ompunds, wherein the aliphatic radicals contain from 8 to 18 carbon atoms, and may be straight chain or branched, and further contain an anionic water-solubilising group, such as carboxyl, sulphonate, sulphate, phosphate or phosphonate.
  • Preferred amphoteric surfactants include: Alkyl betaines, having the structure (57):
  • R 10 is C 1-16 alkyl.
  • alkyl betaine having the structure (57) is lauryldimethyl betaine [eg. EMPIGEN BB, available from Albright & Wilson].
  • Alkylamidopropyl betines, having the structure (58 ) is lauryldimethyl betaine [eg. EMPIGEN BB, available from Albright & Wilson].
  • alkylamidopropyl betaine having the structure (58) is cocamidcpropyl betaine [eg. TEGOBETAIN L7, available from Goldschmidt).
  • Alkylamphoglycinates or Alkylamphopropionates having the structure (59):
  • R 11 is chosen from H, CH 2 COO- and (CH 2 ) 2 COO-, and
  • R 12 is chosen from CH 2 COO- and (CH 2 ) 2 COO- Suitable examples of compounds (59) are
  • cocoamphoglycinate available from GAF
  • R 13 is chosen from C 12 _ 16 alkyl alkylamido groups.
  • An example of a sultaine having the structure (60) is cocamidopropylhydroxysultaine [eg. CYCLOTERIC BET-CS, available from Alcolac).
  • the most preferred amphoteric surfactant are lauryl dimethyl betaine and cocamidopropyl betaine.
  • amphoteric surfactants can contribute to the foaming of the shampoo of the invention, while ameliorating the harshness of the anionic surfactant.
  • the shampoo composition of the invention can also comprise alkoxylated or glycosidic nonionic surfactant having an HLB of 8 or more. Above this value nonionics generally form clear isotropic solutions in combination with the other surfactants in the ranges defined above.
  • Preferred nonionic surfactants are polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers and alkyl p ⁇ lyglycosides.
  • a suitable example of a polyoxyethylene alkyl ester is that having the CTFA designation Polysorbate 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, condensed with approximately 20 moles of ethylene oxide. Also suitable is Polysorbate 20 which is a mixture of laurate esters or sorbitol and sorbitol anhydrides condensed with approximately 20 moles of ethylene oxide.
  • Polysorbate 80 and Polysorbate 20 are available commercially as TWEEN 80 and TWEEN 20 respectively, from ICI Americas.
  • compositions of the invention are also suitable for use in the compositions of the invention.
  • polyethylene glycol ether of C 9-11 alcohol with an average of 8 ethoxy units which is available commercially as NONIDET LE-8T or as SYNPERONIC 91-8T
  • polyethylene glycol ether of C 12-13 alcohol with an average of 9 ethoxy units which is available commercially as DOBANOL 25-9.
  • alkyl polyglycosides include the glycosides of glucose or glucose oligomers where the alkyl chain can be C 8-16 and the average number of glucose units is 1 to 2.
  • a suitable example is ORAMIX NS 10 which is the glucoside of C 10-12 fatty alcohol with an average of about 1.5 glucose units.
  • the amount of surfactant that can be present in the composition accordingly to the invention is up to 30%, preferably from 1 to 20% by weight of the composition.
  • adjuncts examples include antioxidants, such butyl hydroxy toluene; sunscreens, such as octyl methoxycinnamate and butylmethoxy di-benzoyl methane; film forming agents, such as perfluoropolymethylisopropyl ether humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax: plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes. Cosmetic adjuncts can form the balance of the composition. Preservation of the Composition
  • composition according to the invention is preferably preserved in such a manner that it will enjoy an extended shelf life following manufacture and prior to sale and use. Ideally the composition will have an indefinite shelf life.
  • the urea cycle intermediate is likely to be prone to attack by bacteria, moulds and fungi and other microbial influences, particularly at pH values near that of the skin that characterise the preferred composition.
  • the shelf-life of the composition can therefore be unacceptably short due to the biodegradation of the precursor unless steps are taken to preserve the composition.
  • the composition should preferably be free, or substantially free, from viable microbial contaminants that are capable of resulting in microbial spoilage of the composition, and/or biodegradation of the precursor prior to topical application of the composition to mammalian skin or hair. It is to be understood, however, that the invention is also concerned with compositions, as herein defined, which may contain viable but dormant microorganisms, such as bacterial spores, provided that the conditions of preservation do not result in substantial proliferation of the microorganisms prior to use of the composition.
  • composition according to the invention can be preserved by sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry.
  • sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry.
  • composition according to the invention can also be preserved by including in it a chemical preservative which functions to prevent the growth of or kill bacteria, fungi or other microorganisms.
  • Examples of chemical preservatives include ethanol, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sodium propionate and the methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid.
  • the amount of chemical preservative that can be incorporated in the composition according to the invention will generally be from 0.05 to 5%, preferably from 0.1 to 2% by weight, the amount chosen being sufficient to arrest microbial proliferation.
  • composition according to the invention can also be preserved by the inclusion of a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates.
  • a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates.
  • a water activity depressant sufficient should be incorporated in the composition according to the invention to reduce the water activity ( ⁇ w ) from 1 to ⁇ 0.9, preferably to ⁇ 0.85 and most preferably ⁇ 0.8, the lowest of these values being that at which yeasts, moulds and fungi will not proliferate.
  • the topical skin and/or hair treatment composition of the invention can be formulated shampoo or hair conditioner, or as a liquid or gel, or as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
  • the composition can be packaged in a container to suit its viscosity and intended use by the consumer.
  • a shampoo, conditioner, liquid, gel, lotion or fluid cream can be packaged in a bottle or a sachet or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • the composition can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • the invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
  • the invention also provides a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate.
  • a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate.
  • the invention accordingly also provides for the use of a urea cycle intermediate, as herein defined, for topical application to mammalian skin or hair for increasing or maintaining hair growth.
  • compositions according to the invention are primarily intended for topical application to the scalp of the human subject, particularly where the head is already bald or balding, in order to convert vellus hair to growth as terminal hair, or to increase the rate of growth of terminal hair.
  • the compositions can also be applied prophylactically to the hair and hence the scalp to reduce or prevent the onset of baldness, by maintaining the hair in a healthy, growing state, with less that usual hair loss.
  • the amount of the composition and the frequency of application to the hair and/or scalp can vary widely, depending on personal needs, but it is suggested as an example that topical application of from 0.1 to 5g daily containing from 0.00001 to 1g of a selected urea cycle intermediate over the period of at least six months will in most cases result in an improvement in hair growth.
  • This test includes the important step of isolating hair follicles having an undamaged hair bulb from human skin, for example, facelift skin, by microdissection.
  • the method employed is described by Philpott et al; in J Cell
  • the critical step of separating the hair follicle with intact undamaged hair bulb from the subcutaneous fatty tissue in which it is situated accordingly involves severing the hair shaft of the follicle at a point below the epidermis of skin surface, so as to leave the hair bulb intact and undamaged while still bearing a portion of the hair shaft.
  • the hair shaft of the follicle is severed at the dermal-subcutaneous fat interface.
  • Any suitable cutting instrument can be employed to sever the hair shaft in this manner, but a keratotome or a scalpel are preferred.
  • the hair bulb with a hair shaft stump attached is then isolated from the skin by mechanically separating the hair from loosely adhering subcutaneous fat which normally surrounds the hair bulb. This is achieved after the dermis or upper layer of the skin has been separated and removed, to avoid damaging the hair bulb as it is pulled away.
  • the hair bulb together with hair shaft stump attached is then transferred in an otherwise undamaged and fully functioning, viable state to a nutrient medium.
  • the hair follicles isolated by the technique described herein are transferred to a suitable culture medium for subsequent testing of substances that can then influence their future development.
  • isolated hair follicles obtained from facelift skin are maintained in 1 ml of Williams E medium, supplemented with L-glutamine (2mM), insulin (10 ⁇ g/ml), hydrocortisone (10ng/ml) and antibiotics, either with or without a test hair growth substance (urea cycle intermediate).
  • the medium was incubated at 37°C in an atmosphere of 5% CO 2 + 95% air in individual wells of a 24 multiwell dish (Corning), which permits detailed measurements to be made of the length of individual hair follicles.
  • Williams E medium is available from FLOW Laboratory under Catalogue No. 12-502. The formula of Williams E medium is described by Williams GM, et al., in Experimental Cell Research 69 (1971) on page 106.
  • Daily growth rate and cumulative growth for each follicle were calculated by measuring the change in length of the follicles each day using a microscope fitted with an eyepiece graticule and from this the average of all the follicles was calculated.
  • the response of an isolated hair follicle to a test substance can accordingly be assessed by measuring the increase in length, if any, in the presence of a test substance against a control.
  • the in vitro method described herein was used to assess the effect of three urea cycle intermediate, namely arginine hydrochloride, ornithine hydrochloride and citrulline, when used in the presence of- glutamine, compared with glutamine alone, to demonstrate the superiority of the urea cycle intermediates over glutamine alone.
  • a test procedure for total protein synthesis utilised a similar culture of isolated follicles.
  • the follicles were cultured in arginine-deficient Williams E medium supplemented so as to contain 0.287mM, 0.574mM or 1.435mM arginine, for two days. Incubation was then continued for a further three hours in the presence of 14 C labelled leucine as well as the same concentration of arginine as before. After incubation, the follicles were removed from the radioactive media, and washed with 3 x 1ml of PBS
  • the invention is illustrated by the following examples, each of which provides a composition comprising one or more specific metabolic intermediates of the urea cycle or derivatives thereof in in accordance with the invention. Selected metabolic intermediates are indicated by the s gagture numbers l is ted earlier in this specif ication .
  • This Example illustrates a lotion according to the invention which is suitable for topical application to the skin in order to enhance hair growth.
  • the lotion has the following formulation:
  • Example 2 This Example illustrates a hair tonic which is suitable for application to hair or scalp.
  • the hair tonic has the following formulation: % w/w
  • This Example also illustrates a lotion which is suitable for topical application to the scalp.
  • the lotion has the following formulation:
  • This Example also illustrates a hair tonic which is suitable for application to hair or scalp.
  • the hair tonic has the following formulation:
  • the following formulations represent lotions which can be used topically in the treatment of bald or balding male or female heads. % w/w
  • compositions represent creams which can be used in the treatment of baldness. % w/w
  • This Example illustrates a water-in-oil high internal phase emulsion containing an amine according to the invention.
  • the emulsion consisted of 10% by volume oily phase and 90% by weight aqueous phase.
  • the oily phase and the aqueous phase had the following constitution: % w/w
  • the emulsion was prepared by taking 10 parts by volume of the oily phase and to it adding slowly with stirring 90 parts by volume of the aqueous phase.
  • the high internal phase water-in-oil emulsion so formed can be applied topically to the scalp, to improve hair growth and regrowth.
  • examples 14 and 15 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
  • This Example also illustrates a lotion which is suitable for topical application to the scalp.
  • the lotion has the following formulation: % w/w
  • This example illustrates a powder composition according to the invention which can be applied topically to the scalp. % w/w
  • the following example illustrates a lotion according to the invention which can be applied topically to the scalp to prevent hair loss and stimulate hair regrowth. % w/w
  • the hair tonics had the following formulation: % w/w
  • This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
  • the shampoo had the following formulation: % w/w
  • Example 22 This example illustrates a shampoo in accordance with the invention.
  • the shampoo had the following formulation:
  • Example 23 This example illustrates a shampoo in accordance with this invention.
  • the shampoo had the following formulation: % w/w
  • This example illustrates a shampoo in accordance with this invention.
  • the shampoo had the following formulation:
  • Example 25 Water to 100 pH value 6.5 viscosity: 5000 cps (Brookfield Spindle No. 3 at 10 rpm, 25°C)
  • the following examples 25 and 26 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
  • Example 25
  • This Example also illustrates a lotion which is suitable for topical application to the scalp.
  • the lotion has the following formulation: % w/w
  • This example illustrates a powder composition according to the invention which can be applied topically to the scalp.
  • Example 29 The following example illustrates a lotion according to the invention which can be applied topically to the scalp to prevent hair loss and stimulate hair regrowth. % w/w
  • This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
  • the shampoo had the following formulation: % w/w
  • Example 31 This example illustrates a shampoo in accordance with the invention. Firstly a pre-emulsion of polyisobutylene was made by mixing at room temperature the following ingredients in a Winkworth twin-Z-blade mixer (model MZ150). Pre-emulsion ingredient % w/w
  • the pre-emulsion was then mixed, with stirring, with the additional ingredients of . the shampoo. to give a final composition as follows:
  • the shampoo is prepared using a simple hot process whereby all the ingredients except perfume are mixed at 70°C using a paddle stirrer. The mixture is then cooled slowly, and perfume added below 40°C.
  • Silicone emulsion comprises 50% by weight silicone oil (60,000 cs), 4% by weight cetostearyl alcohol and 25% by weight SLES 2E0.
  • ammonium lauryl sulphate/ammonium lauryl ether sulphate and the BHT were heated in the main vessel to 75°C to melt the BHT, with constant stirring.
  • CARBOPOL 1342 was dispersed with stirring in 50% of the water, and the resulting dispersion added to the main vessel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

A cosmetic composition for topical application to mammalian skin or hair, especially to a bald or balding human scalp, contains a metabolic intermediate from the urea cycle, or a derivative of such an intermediate, as an active agent serving to promote growth of hair.

Description

COSMETIC COMPOSITION
FIELD OF THE INVENTION
The invention relates to a cosmetic composition for topical application to mammalian skin or hair for increasing or at least maintaining hair growth, especially terminal hair growth on the human scalp.
BACKGROUND TO THE INVENTION
In recent years, there has been great emphasis on the promotion, enhancement, or at least maintenance of normal hair growth on the human head, particularly with men whose hair has started to recede, as in male pattern baldness, or with both men and women, as hair becomes thinner with advancing age. To this end, the market in "hair restorers" or "baldness cures" is growing.
It is well established that in most mammals, including man, hair does not grow continuously, but undergoes a cycle of activity involving alternate periods of growth and rest.
The hair growth cycle can be divided into three main stages, namely: i) an active stage known as anagen, during which the hair follicle penetrates deep into the dermis with the cells of the bulb dividing rapidly and differentiating to form the hair, ii) a regressive stage known as catagen, which is heralded by the cessation of mitosis, and during which the follicle regresses upwards through the dermis and hair growth ceases, and iii) a resting stage known as telogen, in which the regressed follicle contains a small secondary germ with an underlying ball of tightly packed dermal papilla cells.
The metabolism of the hair follicle during growth is not well understood. It has been established on microdissected hair follicles that glucose is a major fuel which the hair follicle requires for normal growth and that glucose is not oxidised to any great extent, as most of it is converted to lactate. [See, for example, Adachi K, Uno H. Glucose Metabolism of Growing and Resting Hair Follicles. Am J Physiol (1968) 215, 1234-1239; and Philpott M P, Kealey T, Metabolic Studies on Isolated Hair Follicles. J Invest Derm (1991) 96 , 875-879].
In more recent work, we have shown that surprisingly, the hair follicle metabolises very little lipid fuels. Instead, glutamine has emerged as a major fuel which yields as much energy to the hair follicle as does glucose. This work is described in EP 490 581 (Unilever) where we have shown that glutamine stimulates the linear rate of hair growth to a significant extent. This suggests that glutaminolysis is a very important metabolic process for hair growth. As a result of further studies of glutaminolysis, we have now discovered that two thirds of the amine moiety derived from the conversion of glutamine to glutamate cannot be accounted for as ammonia. We therefore investigated its possible fate by examining other metabolic processes in human hair follicles, one of which, we hypothesised, is that the excess amine moieties were being disposed of by a functional urea cycle or part thereof, operating in the follicle.
The importance of the urea cycle for hair growth appears to reside in its ability to produce intermediates important for energy production in the follicle, which in turn enhance the efficiency of glutaminolysis. This is illustrated in Figure 1.
From this linked cycle, it can been seen that specific intermediates play an important part in promoting glutaminolysis. Thus, citrulline, which condenses with aspartate to form argininosuccinate, may also regulate the steps of arginine/urea synthesis by its availability, which would depend on oxaloacetate and in turn TCA cycle intermediates. The availability of arginine may also be important for
RNA and protein biosynthesis due to its being an essential amino acid. The significance of ornithine may be due to its role in the generation of arginine in the follicle rather than to urea. In the process, fumarate is produced which can feed into the TCA cycle and contribute to anaplerotic reactions. Without ornithine and arginine, the ammonia which results from a surplus of nitrogen caused by glutaminolysis may rise to toxic levels and prove fatal to cell function due its inhibition of transaminase reactions and hyperglutaminaemia. We have now put this hypothesis to the test and discovered that supplementing a composition intended for topical application with metabolic intermediates of the urea cycle can cause an increase in hair growth in excess of that previously observed for glutamine.
The invention is accordingly concerned with the use of these intermediates in hair follicle metabolism, so as to increase or maintain hair growth. DEFINITION OF THE INVENTION
Broadly, the invention provides a composition which is suitable for topical application to mammalian skin or hair for increasing, enhancing or maintaining hair growth, which composition comprises:
i) an effective amount of a metabolic intermediate of the urea cycle chosen from arginine, ornithine, citrulline, argininosuccinate, their salts, hydrosalts and precursors thereof, and mixtures thereof; and
ii) a cosmetically acceptable vehicle for the
intermediate.
In another aspect the invention provides a method of increasing, enhancing or maintaining hair growth by use of such a composition. Use is by topical application
especially to the bald or balding human scalp.
DISCLOSURE OF THE INVENTION The Urea Cycle Intermediate
The invention is concerned with the utilisation of a metabolic intermediate which is part of the urea cycle, or a derivative of such a metabolic intermediate, and its topical application for the purposes of increasing or maintaining hair growth, particularly on the human scalp.
The urea cycle and its involvement in glutaminolysis (so important in hair growth) via the tricarboxylic acid (TCA) cycle is shown in Figure 1. From this, four metabolic intermediates of the urea cycle, namely arginine, ornithine, citrulline and argininosuccinate have been selected as possessing the ability to promote linear hair growth to an extent which is significantly greater than glutamine itself.
Each of these four metabolic intermediates can therefore incorporated into a composition for topical application to skin or hair, in particular the scalp, for promoting or at least maintaining hair growth.
It is also possible and indeed is generally more convenient to employ simple derivatives such as salts and hydro salts, as appropriate, of .these metabolic Intermediates. A particularly preferred example of a salt is the sodium salt, and a preferred example of a hydro salt is a
hydrohalide especially the hyrochloride derivatives of these intermediates. It is further possible to employ other derivatives including acyl, ester and peptide derivatives of these metabolic intermediates. These too may be used as salts or hydrosalts.
More particularly, derivatives as shown below in structures (1) to (4) can be employed.
Derivatives of arginine having the structure (1):
Figure imgf000008_0001
Derivatives of ornithine having the structure (2):
Figure imgf000008_0002
Derivatives of citrulline having the structure (3):
Figure imgf000008_0003
Derivatives of argininosuccinate having the structure (4):
Figure imgf000009_0001
where R1 is chosen from: (i) H-,
(ii)
Figure imgf000009_0002
(iii) CxHy- , (iv) amino acid residues, or substituted amino acid residues where any free -NH2 group is modified to form a -NHCOCxHy or a -NHCxHy group, and/or any free -COOH group is substituted to form a COOR2 group, and
(v) peptide residues comprising from 2 to 8 amino acid residues or substituted amino acid residues, which are substituted as defined in (iv) above; the amino acid residues or substituted amino acid residues, as herein defined, being derived from one or more of the following amino acids:
L-α-alanine
L-ß-alanine
L-arginine
L-γ-amino butyric acid
L-asparagine
L-aspartic acid
L-citrulline
L-cysteine
L-cystine
L-3,4-dihydroxyphenylalanine (DOPA)
L-glutamine
L-glutamic acid
L-glycine
L-histidine
L-homoserine
L-hydroxylysine
L-hydroxyproline
L-isoleucine
L-leucine
L-lysine
L-methionine
L-ornithine
L-phenylalanine
L-proline
L-serine
L-threonine
L-N,N,N-trimethyl glycine (betaine)
L-tryptophan
L-tyrosine, and
L-valine; and where each R2 is chosen from:
(i) H+,
(ii) alkali metal cations chosen from Na+ and K+, (iϋ) NH4 + or alkanolammonium ions, and
(iv) CxHy-; where x is a integer of from 1 to 22, and
y is an integer of from 3 to 45; and where each =NH2 + and -NH3 + group is associated with an hydrohalide, where the halide is preferably Cl- or Br-.
Preferred examples of hydrohalide derivatives of urea cycle intermediates are: arginine hydrochloride (10)
ornithine hydrochloride (11) Preferred examples of alkali metal salt derivatives of urea cycle intermediates are: sodium arginate (12)
arginine phosphate, sodium salt (13)
sodium arginosuccinate (14)
potassium arginosuccinate (15)
Preferred examples of dipeptide derivatives of urea cycle intermediates are:
L-α-alanylarginine hydrochloride (15)
L-cystinylornithine (16)
L-methionylcitrulline (17)
L-arginylarginine (18)
L-ornithylcitrulline (19)
L-glutaminylarginine (20)
L-glutaminylcitrulline (21) L-tyrosinylarginine (22)
L-arginylmethionine (23)
L-ornithylmethionine (24)
L-citrullylmethionine (25)
L-arginylaspartate (26)
L-arginylglutamate (27)
L-arginylleucine acetate salt (28)
L-arginyllysine acetate salt (29)
L-arginylphenylalanine acetate salt (30)
L-ornithylaspartate (31) and their corresponding hydrchalides or salts, where appropriate. Preferred examples of other derivatives of urea cycle intermediates are: methylarginine dihydrochloride (32)
arginine ethyl ester dihydrochloride (33)
ethylcitrulline (34)
n-propylornithine (35)
n-octylarginine (36)
n-octylcitrulline (37)
n-octylornithine (38)
The composition can comprise two or more urea cycle intermediates or derivatives thereof, as herein defined.
When the chosen urea cycle intermediate is citrulline, or a derivative thereof, it is preferably to include aspartate in the composition according to the invention, in view of the combination of citrulline and aspartate to from arginosuccinate, as is evident from Figure 1. Likewise, when the chosen urea cycle intermediate is ornithine, or a derivative thereof, it is advantageous to include carbamoyl phosphate in the composition accordingly to the invention, as carbamoyl phosphate promotes the formulation of citrulline from ornithine, as can also be seen from Figure 1. The total amount of the urea cycle intermediate or derivative thereof present in the composition according to the invention is an amount which is sufficient to induce maintain or increase hair growth. This amount will depend on the effectiveness of the intermediate, some being more effective than others, but in general an amount of from 0.001 to 99%, usually from 0.01 to 30% by weight of the composition will provide an adequate concentration for application to the skin, particularly the scalp, which can then be repeated as necessary to promote hair growth.
The Cosmeticallv Acceptable Vehicle
The composition according to the invention also comprises a solid, semi-solid or liquid cosmetically and/or physiologically acceptable vehicle, to enable the urea cycle intermediate, or derivative thereof, to be conveyed to the skin at an appropriate dilution. The nature of the vehicle will depend upon the method chosen for topical administration of the composition. The vehicle can itself be inert or it can possess physiological or pharmaceutical benefits of its own.
The selection of a vehicle for this purpose presents a wide range of possibilities depending on the required product form of the composition. Suitable vehicles can be classified as described hereinafter.
It should be explained that vehicles are substances which can act as diluents, dispersants, or solvents for the urea cycle intermediate, or derivative thereof, which therefore ensure that they can be applied to and distributed evenly over the hair and/or scalp at an appropriate concentration. The vehicle is preferably one which can aid penetration of the esters into the skin to reach the immediate environment of the hair follicle, compositions according to the invention can include water as a vehicle, and/or at least one cosmetically acceptable vehicle other than water.
Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
Emollients, such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, sesame seed oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum jelly, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate;
Propellants, such as propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide; Solvents, such as ethyl alcohol., methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxidε, dimethyl formamide, tetrahydrofuran;
Powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, ethylene glycol distearate;
The cosmetically acceptable vehicle will usually form from 10 to 99.999%, preferably from 10 to 99% and most preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
Activity Enhancer
The composition according to the invention can also optionally comprise an activity enhancer.
The activity enhancer can be chosen from a wide variety of molecules which can function in different ways to enhance the hair growth effects of the urea cycle intermediate. Particular classes of activity enhancers include (a) other hair growth stimulants, (b) penetration enhancers and (c) cationic polymers, whose presence can further improve the delivery of the ester through the stratum corneum to its site of action in the immediate environment of the hair follicle.
Some activity enhancers can also function as vehicles for the ester. (a) Other Hair Growth Stimulants i. Examples of other substances which themselves possess the ability to stimulate or increase hair growth include, for example:
Benzalkonium chloride
Benzethonium chloride
Phenol
Estradiol
Diphenhydramine hydrochloride
Chlorpheniramine maleate
Chlorophyllin derivatives
Cholesterol
Salicylic acid
Cystine
Methionine
Red pepper tincture
Benzyl nicotinate
dl-Menthol
Peppermint oil
Calcium pantothenate
Panthenol
Castor oil
Hinokitiol
Prednisolone
Resorcinol
Further substances which themselves possess the ability to increase the rate of terminal hair growth include: ii(a) α-1,4 Esterified disaccharides described by Choay
S.A. in EP-A 0 064 012; and ii(b) Esterified oligosaccharides as described by
Unilever in EP-A 0 211 610. iii. Minoxidil glucuronides, as described by Unilever in EP 0 242 967. iv. Minoxidil sulphates, as described by The Upjohn
Co. in WO 86/04231. v. Minoxidil, and other derivatives thereof as described by The Upjohn Co. in US 4 139 619. vi. Ethylenediaminetetraacetic acid or salts thereof, as described by Redken Laboratories, Inc. in US 4 814 351. vii. Direct proteoglycanase inhibitors, such as 1,10- phenanthroline, as described by Unilever in EP 0 277 428. viii. Glycosaminoglycanase inhibitors, as described by
Unilever in EP 0 277 428, such as D-Glucaro-1,4- lactone. ix. Glycosaminoglycanase inhibitors, as described by
Unilever in EP 0 277 428, such as N- acetylglucosamine. x. Glycosaminoglycan chain cellular uptake inhibitors, as described by Unilever in EP 0 277 428, such as hexuronic acid and esters thereof. xi. Chemical inhibitors of glycosidase activity, as described by Unilever in EP 0 334 586, chosen from lactams, such as D-glucaro-1,5-lactam. xii. Chemical activators of protein kinase C enzymes, as described by Unilever in EP 0 334 585 chosen from diacylglycerols, such as 1,2-Dioleoyl-sn- glycerol.
Xlll. Glycosaminoglycanase inhibitors, as described by
Unilever in EP 0 348 184, such as 6-methyl- glucaro-1,4-lactone. xiv. Glycosaminoglycanase inhibitors, as described by
Unilever in EP 0 348 184, chosen from acylated monosaccharides, such as 2-propionamido-2- deoxyglucose. xv. Esters of pyroglutamic acid, as described by
Lever Brothers Company in US 4 774 255, such as pyroglutamic acid n-hexyl ester and pyroglutamic acid n-octyl ester. xvi. Hexosaccharic acids or an acylated hexosacchariσ acids, or salts or esters thereof, as described by Unilever in EP 378 388, such as glucosaccharic acid, and its disodium salt. xvii. Aryl-substituted ethylenes as described by
Unilever in EP 403 238, such as 1,1-dicarboxy-2- (4-hydroxyphenyl)ethylene.
(b) Penetration Enhancers
As has been stated earlier, the presence of a penetration enhancer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery through the stratum corneum to its site of action in the hair follicle. The penetration enhancer can accordingly function in a variety of ways. It can for example, improve the distribution of the urea cycle intermediate on the skin surface or, it can increase its partition into the skin from the composition when applied topically, so aiding its passage to its site of action. Other mechanisms enhancing the benefit of the hair growth promoter may also be involved.
Examples of penetration enhancers include:
2-methyl propan-2-ol
Propan-2-ol
Ethyl-2-hydroxypropanoate
Hexan-2,5-diol
POE(2) ethyl ether
Di(2-hydroxypropyl) ether
Pentan-2,4-diol
Acetone
POE(2) methyl ether
2-hydroxypropionic acid
2-hydroxyoctanoic acid
Propan-1-ol
1,4 Dioxane
Tetrahydrofuran
Butan-1,4-diol
Propylene glycol dipelargonate
Polyoxypropylene 15 stearyl ether
Octyl alcohol
POE ester of oleyl alcohol
Oleyl alcohol
Lauryl alcohol
Dioctyl adipate
Dicapryl adipate
Diisopropyl adipate
Diisopropyl sebacate
Dibutyl sebacate
Diethyl sebacate
Dimethyl sebacate
Dioctyl sebacate Dibutyl suberate
Dioctyl azelate
Debenzyl sebacate
Dibutyl phthalate
Dibutyl azelate
Ethyl myristate
Dimethyl azelate
Butyl myristate
Dibutyl succinate
Dideσyl phthalate
Decyl oleate
Ethyl caproate
Ethyl salicylate
Isopropyl palmitate
Ethyl laurate
2-ethyl-hexyl pelargonate
Isopropyl isostearate
Butyl laurate
Benzyl benzoate
Butyl benzoate
Hexyl laurate
Ethyl caprate
Ethyl caprylate
Butyl stearate
Benzyl salicylate
2-hydroxypropanoic acid
2-hyroxyoctanoic acid.
Dimethyl sulphoxide
N,N-Dimethyl acetamide N,N-Dimethyl formamide
2-Pyrrolidone
l-Methyl-2-pyrrolidone
5-Methyl-2-pyrrolidone
1,5-Dimethyl-2-pyrrolidone 1-Ethyl-2-pyrrolidone
Phosphine oxides
Sugar esters Tetrahydrofurfural alcohol
Urea
Diethyl-m-toluamide, and
1-Dodecylazacyloheptan-2-one
(c) Cationic Polymers
As stated earlier, the presence of a cationic polymer can potentiate the benefit of the urea cycle intermediate or derivative thereof by improving its delivery to the hair and scalp. Examples of preferred cationic polymers include:
Guar Hydroxypropyltrimonium chloride
Quaternium-19
Quaternium-23
Quaternium-40
Quaternium-57
Poly(dipropyldiallylammonium chloride)
Poly(methyl-γ-propaniodiallylammonium chloride)
Poly(diallylpiperidinium chloride)
Poly(vinyl pyridinium chloride)
Quaternised poly (vinyl alcohol)
Quaternised poly (dimethylaminoethylmethacrylate); and mixtures thereof
The amount of activity enhancer, when employed in accordance with the invention, will normally be from 0.1 to 50%, preferably from 0.5 to 25% and most preferably from 0.5 to 10% by weight of the composition.
OPTIONAL SKIN BENEFIT MATERIALS AND COSMETIC ADJUNCTS
A particularly convenient form of the composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed. Oil or oily material
The composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
Examples of suitable oils include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients. Other oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.
The oil or oily material, when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
Emulsifier The composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or and oil-in-water emulsion is formed. When a water-in-oil emulsion is required, the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6. When an oil-in-water emulsion is required, a chosen emulsifier or emulsifiers should have an average HLB value of >6.
Examples of suitable emulsifiers are set below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
Table 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Chemical Name Trade Name HLB Value of Emulsifier
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Sorbitan trioleate Arlacel 85 1.8 Sorbitan tristearate Span 65 2.1 Glycerol monooleate Aldo MD 2.7 Glycerol monostearate Atmul 84S 2.8 Glycerol monolaurate Aldo MC 3.3 Sorbitan sesquioleate Arlacel 83 3.7 Sorbitan monooleate Arlacel 80 4.3 Sorbitan monostearate Span 60 4.7 Poloxyethylene (2)
stearyl ether Brij 72 4.9 Poloxyethylene sorbitol
beeswax derivative G-1702 5
PEG 200 dilaurate Emerest 2622 6.3 Sorbitan monopalraitate Arlacel 40 6.7 Polyoxyethylene (3.5)
nonyl phenol Emulgen 903 7.8 PEG 200 monostearate Tegester PEG
200 MS 8.5
Sorbitan monolaurate Arlacel 200 8.6 PEG 400 dioleate Tegester PEG
400-DO 8.8
Polyoxyethylene (5)
monostearate Ethofat 60-16 9.0 Polyoxyethylene (4) sorbitan
monostearate Tween 61 9.6 Polyoxyethylene (4) lauryl
ether Brij 30 9.7 Polyoxyethylene (5) sorbitan
monooleate Tween 81 10.0 PEG 300 monooleate Neutronyx 834 10.4 Polyoxyethylene (20)
sorbitan tristearate Tween 65 10.5
Polyoxyethylene (20)
sorbitan trioleate Tween 85 11.0 Polyoxyethylene (8)
monostearate Myrj 45 11.1 PEG 400 monooleate Emerest 2646 11.7
PEG 400 monostearate Tegester PEG 400 11.9 Polyoxyethylene 10
monooleate Ethofat 0/20 12.2 Polyoxyethylene (10)
stearyl ether Brij 76 12.4
Polyoxyethylene (10)
cetyl ether Brij 56 12.9 Polyoxyethylene (9.3)
octyl phenol Triton X-100 13.0 Polyoxyethylene (4)
sorbitan monolaurate Tween 21 13.3 PEG 600 monooleate Emerest 2660 13.7 PEG 1000 dilaurate Kessco 13.9 Polyoxyethylene sorbitol
lanolin derivative G-1441 14.0
Polyoxyethylene (12)
lauryl ether Ethosperse LA-12 14.4 PEG 1500 dioleate Pegosperse 1500 14.6 Polyoxyethylene (14)
laurate Arosurf HFL-714 14.8
Polyoxyethylene (20)
sorbitan monostearate Tween 60 14.9 Polyoxyethylene 20 sorbitan
monooleate Tween 80 15.0 Polyoxyethylene (20)
stearate Myrj 49 15.0 Polyoxyethylene (20)
stearyl ether Brij 78 15.3 Polyoxyethylene (20)
sorbitan monopalmitate Tween 40 15.6 Polyoxyethylene (20) cetyl
ether Brij 58 15.7 Polyoxyethylene (25)
oxypropylene
monostearate G-2162 16.0 Polyoxyethylene (20)
sorbitol monolaurate Tween 20 16.7 Polyoxyethylene (23)
lauryl ether Brij 35 16.9 Polyoxyethylene (50)
monostearate Myrj 53 17.9 PEG 4000 monostearate Pegosperse 4000
MS 18.7- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
The foregoing list of emulsifiers is not intended to be limiting and merely exemplifies selected emulsifiers which are suitable for use in accordance with the invention.
It is to be understood that two or more emulsifiers can be employed if desired.
The amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
Water
The composition of the invention can also comprise water, usually up to 90%, preferably from 5 to 80% by volume. Water can function as the cosmetically acceptable vehicle.
Silicone Surfactant
The composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
The silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight from 10,000 to 50,000.
The dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane. Ideally, the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.
Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).
A particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C
Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
The amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion. Surfactants
The composition for use in the method according to the invention can be formulated as a shampoo and will then accordingly comprise one or more surfactants which are cosmetically acceptable and suitable for topical
application to the hair. Examples of suitable shampoo surfactants are given below. When a composition is formulated to contain surfactant in a quantity of 4% by weight or more, it may prove desirable to use the
metabolic intermediate in a concentration of more than 5% by weight, possibly more than 8% by weight. This may even prove desirable when surfactant is present in lower concentrations, such as 1% by weight or more. Anionic Surfactant
The composition of the invention can comprise an anionic surfactant which is preferably chosen from alkyl sulphate, alkyl ether sulphate, alkyl sulphonate, alkyl aryl sulphonate, olefin sulphonate, acyl sarcosinate, acyl tauride, acyl isethionate, nonoalkyl sulphosuccinate, dialkylsulphosuccinate, acryl lactylate, acylated α-amino acid, alkyl carboxylate, monoalkyl phosphate and dialkyl phosphate.
Specific examples of anionic surfactants include: alkyl sulphates, such as sodium lauryl sulphate [eg.
EMPICOL CX available from Albright & Wilson], and
triethanolamine lauryl sulphate [eg. EMPICOL TL40/T, availa le from Albright & Wilson]. alkylether sulphates, such as sodium lauryl ether sulphate
[eg. EMPICOL ESB70, available from Albright & Wilson]. alkyl sulphonates, such as sodium alkane (C13-18) sulphonate [eg. HOSTAPUR SAS 30, available from Hoechst]. alkylaryl sulphonates, such as sodium alkyl benzene sulphonate [eg. TEEPOL CM44, available from Shell]. olefin sulphonates. such as sodium olefin sulphonate (C5-18) [eg. HOSTAPUR OS, available from Hoechst]. acyl sarcosinates. having the structure: (51)
Figure imgf000028_0001
where R3 is chosen from C6-14 alkyl, and
M is a counterion chosen from alkali metals, ammonium and substituted ammonium such as alkanolammonium.
An example of an acyl sarcosinate having the structure (51), is sodium lauryl sarcosinate [eg. HAMPOSYL L-95, available from Grace] . acyl taurides, having the structure (52):
Figure imgf000028_0002
where R4 is chosen from C8-18 alkyl
An example of an acyl tauride having the structure (52) is coconut methyl taurine [eg. FENOPEN TC 42, available from GAF]. acyl isethionates , having the structure ( 53 ) :
Figure imgf000029_0001
where R5 is chosen from C8-18 alkyl. An example of an acyl isethionate having the structure (53) is sodium acyl isethionate [eg. JORDAPON Cl, available from Jordon]. monoalkyl sulphosuccinates, having the structure (54) :
Figure imgf000029_0002
where R6 is chosen from C10-20 alkyl.
Examples of monoalkyl sulphosuccinates having the structure (54) include: sodium lauryl sulphosuccinate [eg. EMPICOL SLL, available from Albright & Wilson]. magnesium alkyl sulphosuccinate [eg. ELFANOL 616 Mg, available from AKZO]. sodium lauryl ethoxysulphosuccmate [eg. EMPICOL SDD, available from Albright & Wilson]. coconut monoethanolamide ethoxysulphosuccmate [eg. EMPICOL SGG]. disodium lauryl polyglycolether sulphosuccinate [eg. SURTAGENE S30, available from CHEM-Y]. polyethyleneglycol sulphosuccinate [eg. REWOPOL SBFA 30, available from REWO]. dialkyl sulphosuccinates, having the structure (55):
Figure imgf000030_0001
where R7 and R8 are the same or different, and are chosen from C6-14 alkyl.
An example of a dialkyl sulphosuccinate having the structure (55) is sodium dilauryl sulphosuccinate [eg. EMCOL 4500, available from Witco]. acyl lactylates, having the structure (56):
Figure imgf000030_0002
where R9 is chosen from C6-16 alkyl, and n is 1 or 2.
An example of an acyl lactylate having the structure (6) is decanoyl lactylate [eg. PATIONIC 122a, available from Patterson, CJ]. acylated a-amino acids, such as sodium lauroyl glutamate [eg. ACYLGLUTAMATE LS-11, available from Ajinomoto Co. Inc]. ethyl carboxlates such as alkyl C12-14O(EO)4OCH2CO2Na [eg. AKYPO RLM 38, available from Akzo]. monoalkyl phosphates such as monolauryl phosphate, and dialkyl phosphates. such as dioctyl phosphate.
Amphoteric Surfactant
The shampoo compositions of the invention also comprise amphoteric surfactant. Suitable amphoteric surfactants are derivatives of aliphatic quaternary ammonium, phosphonium and sulphonium σompunds, wherein the aliphatic radicals contain from 8 to 18 carbon atoms, and may be straight chain or branched, and further contain an anionic water-solubilising group, such as carboxyl, sulphonate, sulphate, phosphate or phosphonate.
Preferred amphoteric surfactants include: Alkyl betaines, having the structure (57):
Figure imgf000031_0001
where R10 is C1-16 alkyl.
An example, of an alkyl betaine having the structure (57) is lauryldimethyl betaine [eg. EMPIGEN BB, available from Albright & Wilson]. Alkylamidopropyl betines, having the structure (58 ) :
Figure imgf000032_0003
An example of an alkylamidopropyl betaine having the structure (58) is cocamidcpropyl betaine [eg. TEGOBETAIN L7, available from Goldschmidt).
Alkylamphoglycinates or Alkylamphopropionates having the structure (59):
Figure imgf000032_0002
where R11 is chosen from H, CH2COO- and (CH2)2COO-, and
R12 is chosen from CH2COO- and (CH2)2COO- Suitable examples of compounds (59) are
cocoamphoglycinate (available from GAF), and
cocoamphopropionate.
Sultaines, having the structure (60)
Figure imgf000032_0001
where R13 is chosen from C12_16 alkyl alkylamido groups. An example of a sultaine having the structure (60) is cocamidopropylhydroxysultaine [eg. CYCLOTERIC BET-CS, available from Alcolac). The most preferred amphoteric surfactant are lauryl dimethyl betaine and cocamidopropyl betaine.
Such amphoteric surfactants can contribute to the foaming of the shampoo of the invention, while ameliorating the harshness of the anionic surfactant.
Nonionic Surfactant
The shampoo composition of the invention can also comprise alkoxylated or glycosidic nonionic surfactant having an HLB of 8 or more. Above this value nonionics generally form clear isotropic solutions in combination with the other surfactants in the ranges defined above. Preferred nonionic surfactants are polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers and alkyl pσlyglycosides.
A suitable example of a polyoxyethylene alkyl ester is that having the CTFA designation Polysorbate 80 which is a mixture of oleate esters of sorbitol and sorbitol anhydrides, condensed with approximately 20 moles of ethylene oxide. Also suitable is Polysorbate 20 which is a mixture of laurate esters or sorbitol and sorbitol anhydrides condensed with approximately 20 moles of ethylene oxide.
Polysorbate 80 and Polysorbate 20 are available commercially as TWEEN 80 and TWEEN 20 respectively, from ICI Americas.
Also suitable for use in the compositions of the invention is the polyethylene glycol ether of C9-11 alcohol with an average of 8 ethoxy units, which is available commercially as NONIDET LE-8T or as SYNPERONIC 91-8T, and the polyethylene glycol ether of C12-13 alcohol with an average of 9 ethoxy units which is available commercially as DOBANOL 25-9.
Particularly useful alkyl polyglycosides include the glycosides of glucose or glucose oligomers where the alkyl chain can be C8-16 and the average number of glucose units is 1 to 2. A suitable example is ORAMIX NS 10 which is the glucoside of C10-12 fatty alcohol with an average of about 1.5 glucose units.
The amount of surfactant that can be present in the composition accordingly to the invention is up to 30%, preferably from 1 to 20% by weight of the composition.
Other Cosmetic Adjuncts Examples of conventional adjuncts which can optionally be employed include antioxidants, such butyl hydroxy toluene; sunscreens, such as octyl methoxycinnamate and butylmethoxy di-benzoyl methane; film forming agents, such as perfluoropolymethylisopropyl ether humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax: plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes. Cosmetic adjuncts can form the balance of the composition. Preservation of the Composition
The composition according to the invention is preferably preserved in such a manner that it will enjoy an extended shelf life following manufacture and prior to sale and use. Ideally the composition will have an indefinite shelf life.
It is accordingly apparent that the urea cycle intermediate is likely to be prone to attack by bacteria, moulds and fungi and other microbial influences, particularly at pH values near that of the skin that characterise the preferred composition. The shelf-life of the composition can therefore be unacceptably short due to the biodegradation of the precursor unless steps are taken to preserve the composition.
In order to be preserved, the composition should preferably be free, or substantially free, from viable microbial contaminants that are capable of resulting in microbial spoilage of the composition, and/or biodegradation of the precursor prior to topical application of the composition to mammalian skin or hair. It is to be understood, however, that the invention is also concerned with compositions, as herein defined, which may contain viable but dormant microorganisms, such as bacterial spores, provided that the conditions of preservation do not result in substantial proliferation of the microorganisms prior to use of the composition.
Examples of the methods that can be employed to achieve preservation of the composition, includes the following: (i) Sterilisation
The composition according to the invention can be preserved by sterilisation to remove or kill substantially all viable microbial contaminants. This can be achieved for example by irradiation using a lethal dose of gamma rays, by heat sterilisation or by ultrafiltration using techniques that are well established in the pharmaceutical industry. (ii) Chemical Preservative
The composition according to the invention can also be preserved by including in it a chemical preservative which functions to prevent the growth of or kill bacteria, fungi or other microorganisms.
Examples of chemical preservatives include ethanol, benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, sodium propionate and the methyl, ethyl, propyl and butyl esters of p-hydroxybenzoic acid. The amount of chemical preservative that can be incorporated in the composition according to the invention will generally be from 0.05 to 5%, preferably from 0.1 to 2% by weight, the amount chosen being sufficient to arrest microbial proliferation.
(iii) Water activity depressants The composition according to the invention can also be preserved by the inclusion of a water activity depressant such as glycerol, propylene glycol, sorbitol, sugars and salts, for examples alkali metal halides sulphates and carboxylates. When employing a water activity depressant, sufficient should be incorporated in the composition according to the invention to reduce the water activity (αw) from 1 to < 0.9, preferably to < 0.85 and most preferably < 0.8, the lowest of these values being that at which yeasts, moulds and fungi will not proliferate.
PRODUCT FORM AND PACKAGING
The topical skin and/or hair treatment composition of the invention can be formulated shampoo or hair conditioner, or as a liquid or gel, or as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
The composition can be packaged in a container to suit its viscosity and intended use by the consumer. For example, a shampoo, conditioner, liquid, gel, lotion or fluid cream can be packaged in a bottle or a sachet or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
Process The invention also provides a process for preparing a hair growth composition which comprises the steps of mixing an effective amount of a urea cycle intermediate, as herein defined, together with a cosmetically acceptable carrier for the intermediate. Use of the urea cycle intermediate for increasing or maintaining hair growth
The invention accordingly also provides for the use of a urea cycle intermediate, as herein defined, for topical application to mammalian skin or hair for increasing or maintaining hair growth.
The compositions according to the invention are primarily intended for topical application to the scalp of the human subject, particularly where the head is already bald or balding, in order to convert vellus hair to growth as terminal hair, or to increase the rate of growth of terminal hair. The compositions can also be applied prophylactically to the hair and hence the scalp to reduce or prevent the onset of baldness, by maintaining the hair in a healthy, growing state, with less that usual hair loss. The amount of the composition and the frequency of application to the hair and/or scalp can vary widely, depending on personal needs, but it is suggested as an example that topical application of from 0.1 to 5g daily containing from 0.00001 to 1g of a selected urea cycle intermediate over the period of at least six months will in most cases result in an improvement in hair growth.
EVALUATION OF EFFICACY OF THE UREA CYCLE INTERMEDIATES USING THE IN VITRO HAIR FOLLICLE GROWTH TEST
The effect of compounds on hair growth was assessed using an in vitro test which measures the elongation of isolated human hair follicles in a culture medium. Isolation of the hair follicle from skin
This test includes the important step of isolating hair follicles having an undamaged hair bulb from human skin, for example, facelift skin, by microdissection. The method employed is described by Philpott et al; in J Cell
Sci 97, 463, (1990).
The critical step of separating the hair follicle with intact undamaged hair bulb from the subcutaneous fatty tissue in which it is situated accordingly involves severing the hair shaft of the follicle at a point below the epidermis of skin surface, so as to leave the hair bulb intact and undamaged while still bearing a portion of the hair shaft.
Preferably, the hair shaft of the follicle is severed at the dermal-subcutaneous fat interface. Any suitable cutting instrument can be employed to sever the hair shaft in this manner, but a keratotome or a scalpel are preferred.
The hair bulb with a hair shaft stump attached is then isolated from the skin by mechanically separating the hair from loosely adhering subcutaneous fat which normally surrounds the hair bulb. This is achieved after the dermis or upper layer of the skin has been separated and removed, to avoid damaging the hair bulb as it is pulled away.
The hair bulb together with hair shaft stump attached, is then transferred in an otherwise undamaged and fully functioning, viable state to a nutrient medium. Culture of the isolated hair follicle
The hair follicles isolated by the technique described herein are transferred to a suitable culture medium for subsequent testing of substances that can then influence their future development.
The procedure now to be described represents a preferred method of culture and testing of hair growth.
In accordance with the preferred method of culture, isolated hair follicles, obtained from facelift skin are maintained in 1 ml of Williams E medium, supplemented with L-glutamine (2mM), insulin (10 μg/ml), hydrocortisone (10ng/ml) and antibiotics, either with or without a test hair growth substance (urea cycle intermediate). The medium was incubated at 37°C in an atmosphere of 5% CO2 + 95% air in individual wells of a 24 multiwell dish (Corning), which permits detailed measurements to be made of the length of individual hair follicles.
Williams E medium is available from FLOW Laboratory under Catalogue No. 12-502. The formula of Williams E medium is described by Williams GM, et al., in Experimental Cell Research 69 (1971) on page 106.
Daily growth rate and cumulative growth for each follicle were calculated by measuring the change in length of the follicles each day using a microscope fitted with an eyepiece graticule and from this the average of all the follicles was calculated.
Evaluation of Results
The response of an isolated hair follicle to a test substance, can accordingly be assessed by measuring the increase in length, if any, in the presence of a test substance against a control. The in vitro method described herein was used to assess the effect of three urea cycle intermediate, namely arginine hydrochloride, ornithine hydrochloride and citrulline, when used in the presence of- glutamine, compared with glutamine alone, to demonstrate the superiority of the urea cycle intermediates over glutamine alone.
The results obtained are summarised in the following Table 2 below.
Figure imgf000042_0001
Figure imgf000043_0001
The results summarised in Table 2 above indicate the significant increase in hair growth, as compared with glutamine alone (control), that can be achieved with each of the urea cycle intermediates in the presence of glutamine, as promoters of th rate of hair growth. This confirms that urea cycle intermediate promote or at least maintain hair growth.
In a similar experiment, using Williams E medium as the control, and Williams E medium supplemented with 1mM arginine as the test medium, it was found that there was some variation in the percentage Increase in hair growth for follicles from three different patients. The percentages were 7%, 3.5% and 6% increase in hair growth compared to controls from the same patients. The average of 5.5%
increase in hair growth was clearly statistically significant.
Like experiments was carried out using 1 mM ornithine and 1mM citrilline as the supplement to the Williams E medium. The results with follicles from each patient were statistically significant and averaged 7.4% for citrulline and 6.4% for ornithine.
A test procedure for total protein synthesis utilised a similar culture of isolated follicles. The follicles were cultured in arginine-deficient Williams E medium supplemented so as to contain 0.287mM, 0.574mM or 1.435mM arginine, for two days. Incubation was then continued for a further three hours in the presence of 14C labelled leucine as well as the same concentration of arginine as before. After incubation, the follicles were removed from the radioactive media, and washed with 3 x 1ml of PBS
supplemented with 10mM unlabelled leucine, to displace non-covalently bound 14C-leucine. They were then
homogenised in 1ml of ice-cold 0.1M K2EDTA, pH 12.3, in a hand-held glass/glass homogeniser. The homogenate was left at 4°C for 30 min. to release and dissolve the protein. Cell debris was removed by centrifugation, and 110μl samples of the supernatant removed for total protein determination by the Bio-Rad assay [based on Bradford, Anal.Biochem., 72, 248 (1976)]. To the remaining
supernatant was added 0.5ml of ice-cold 15% TCA, and this was left at 4°C for 15 min. to precipitate out the
protein. The precipitate was collected, and washed with 4 × 5ml of 15% TCA, under vacuum onto Whatman GF/C (2.4cm) filters, which had been pre-washed with PBS supplemented with 10mM unlabelled leucine. Finally, the filters were dried and their radioactivity determined by liquid
scintillation spectrometry. The cell debris was
solubilised in 0.5ml of Soluene, and counting its
radioactivity showed that less than 15% of incorporated radioactivity was discarded in the cell debris pellet. The results were:
Arginine concentration Leucine uptake
(mM) (pmol/hour/follicle)
0 .287 80
0 . 574 93
1 .435 110
This showed that the arginine was enhancing protein synthesis in the hair follicles .
EXAMPLES
The invention is illustrated by the following examples, each of which provides a composition comprising one or more specific metabolic intermediates of the urea cycle or derivatives thereof in in accordance with the invention. Selected metabolic intermediates are indicated by the s tructure numbers l is ted earlier in this specif ication .
Example 1
This Example illustrates a lotion according to the invention which is suitable for topical application to the skin in order to enhance hair growth.
The lotion has the following formulation:
% w/w
Intermediate (10) 1
ethanol 99
perfume q.s.
Example 2 This Example illustrates a hair tonic which is suitable for application to hair or scalp.
The hair tonic has the following formulation: % w/w
intermediate (11) 2
ethanol 49
water 49
perfume q.s.
Example 3
This Example also illustrates a lotion which is suitable for topical application to the scalp.
The lotion has the following formulation:
% w/w
Intermediate (12) 3
propan-2-ol 10
ethanol 87
perfume q.s. Example 4
This Example also illustrates a hair tonic which is suitable for application to hair or scalp.
The hair tonic has the following formulation:
% w/w
Intermediate (13) 3
ethanol 40
water 57
perfume q.s.
Examples 5 to 8
The following formulations represent lotions which can be used topically in the treatment of bald or balding male or female heads. % w/w
5 6 2 8
Hydroxyethyl cellulose 0.4 - 0.4 -
Absolute ethanol 25 25 25 25
Propane-1,2-diol - - 38.4 38.4
Butane-1,3-diol 38.4 38.8 - -
Paramethyl benzoate 0.2 0.2 0.2 0.2
Intermediate (14) 5 - - -
Intermediate (15) - 4 - -
Intermediate (16) - - 3 -
Citrulline - - - 4
N-acetyl proline 0.6 0.6 0.6 0.6
Perfume 1 1 1 1
Water to 100 100 100 100 Examples 9 to 12
The following formulations represent creams which can be used in the treatment of baldness. % w/w
9 10 11 12
Cetyl alcohol
polyoxyethylene (10) 4 4 4 4
Cetyl alcohol 4 4 4 4
Mineral oil 4 2 - - Paraffin wax - 2 4 - Intermediate (17) - - - 4
Intermediate (18) 2 - - - Intermediate (19) - 2
- - - Intermediate (20) - - 2 - minoxidil 0.5 0.5 0.5 0.5 Triethanolamine 0.75 0.75 0.75 0.75 Butane-1,3-diol 3 3 3 3
Xanthan gum 0.3 0.3 0.3 0.3 Preservative 0.4 0.4 0.4 0.4 Perfume q.s. q.s. q.s. q.s.
Water to 100 100 100 100
Example 13
This Example illustrates a water-in-oil high internal phase emulsion containing an amine according to the invention.
The emulsion consisted of 10% by volume oily phase and 90% by weight aqueous phase. The oily phase and the aqueous phase had the following constitution: % w/w
Oily phase
Sorbitan monooleate 20
Quaternium-18 hectorite 5
Liquid paraffin 75
Agueous phase
Intermediate (21) 1
Xanthan gum 1
Preservative 0.3
Perfume q.s.
Sodium chloride (1% w/w solution) to 100
The emulsion was prepared by taking 10 parts by volume of the oily phase and to it adding slowly with stirring 90 parts by volume of the aqueous phase.
The high internal phase water-in-oil emulsion so formed can be applied topically to the scalp, to improve hair growth and regrowth.
The following.two examples 14 and 15 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp.
Example 14 % w/w
Sodium lauryl ether sulphate
(2 EO) [21% AD] 41.4
Lauryl dimethylamino acetic acid
betaine: [30% AD] 4
Coconut fatty acid diethanolamine 1.5
Oleyl triethoxy phosphate (BRIPHOS 03D) 1
Polyglycol-polyamine condensation
resin (POLYQUART H) [50% active] 1.5
Preservative, colouring matter, salt 0.58 Intermediate (22) 10
Perfume q.s.
Water to 100
Example 15 % w/w
Sodium lauryl ether sulphate (2 EP)
[100% AD] 12
POLYMER JR400 2.5
BRIPHOS 03D 2.5
Intermediate (23) 15
Magnesium Sulphate 5
Perfume q.s.
Water to 100
Example 16
This Example also illustrates a lotion which is suitable for topical application to the scalp.
The lotion has the following formulation: % w/w
Intermediate (24) 5
minoxidil 1
propan-2-ol 10
ethanol 84 Example 17
This example illustrates a powder composition according to the invention which can be applied topically to the scalp. % w/w
Chemically modified starch 5
Chemically modified cellulose - Boric acid 10
Zinc oxide 5.
Intermediate (25) 3
Minoxidil 5
Perfume q.s.
Chalk 10
Talc to 100
Example 18
The following example illustrates a lotion according to the invention which can be applied topically to the scalp to prevent hair loss and stimulate hair regrowth. % w/w
Intermediate (26) 7
glucaro-1,4-lactone 2
ethanol 16
citric acid 1.05
water to 100 pH adjusted to 4.2 with sodium hydroxide
Examples 19 and 20
These examples illustrate hair tonics which are suitable for application to the hair and scalp.
The hair tonics had the following formulation: % w/w
19 20
Intermediate (27) - 2
Intermediate (28) 2 - glucaro-1,5-lactam 3 3 ethanol 50 50 water 45 45 Example 21
This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
The shampoo had the following formulation: % w/w
Triethanolamine lauryl
sulphate 16.8
Coconut diethanolamide 3.0
Hydroxypropylmethyl- cellulose (1) 0.25
Corn syrup (80% solids) (2) 20.5
Dimethylpolysiloxane (3) 1.0
Cationic cellulose (4) 0.5
Ethyl alcohol (SDA 40) 9.0
Vinyl carboxy polymer (5) 0.75
Intermediate (29) 8
Perfume, colour, preservative q.s.
Water to 100 Acid or base to pH: 6.5
1 - Methocel E4M (Dow Chemical)
2 - 42 Dextrose equivalent (Staley 1300)
3 - 60,000 centistokes (Viscasil, GEC)
4 - Polymer JR 400
5 - Carbopol 941 (BF Goodrich)
Example 22 This example illustrates a shampoo in accordance with the invention. The shampoo had the following formulation:
% w/w
Sodium lauryl ether sulphate (3EO) 10
Pearlising agent 4
Betaine 2
Cationic polymer 0.2
Intermediate (30) 6.5
minor ingredients 4
water to 100 pH value 6 to 7 viscosity: 3500 to 4000 cps (Brookfield Spindle No. 3 at 10 rpm 25°C)
Example 23 This example illustrates a shampoo in accordance with this invention.
The shampoo had the following formulation: % w/w
Sodium lauryl ether sulphate [3EO] (70%AD) 20
Pearlising agent 2
Betaine 6
Intermediate (31) 7
glutamine 1
Silicone emulsion 1
Cationic polymer 0.1
D-panthenol 0.4
Carbopol 0.4
Sodium chloride 2.5
Minor ingredients 8.5
Water to 100 pH value 6. 5 viscosity: 5000 cps (Brookfield Spindle No. 3 at 10 rpm, 25°C) Example 24
This example illustrates a shampoo in accordance with this invention. The shampoo had the following formulation:
% w/w
Sodium lauryl ether sulphate [3EO] (70 %AD) 20
Pearlising agent 2
Betaine 6
Intermediate (32) 7
glutamine 1
Silicone emulsion 1
Cationic polymer 0.1
D-panthenol 0.4
Carbopol 0.4
Sodium chloride 2.5
Minor ingredients 8.5
Water to 100 pH value 6.5 viscosity: 5000 cps (Brookfield Spindle No. 3 at 10 rpm, 25°C) The following examples 25 and 26 illustrate shampoos for use in washing the hair and scalp, and for promoting hair growth on the scalp. Example 25
% w/w
Sodium lauryl ether sulphate
(2 EO) [21% AD] 41.4
Lauryl dimethylamino acetic acid
betaine: [30% AD] 4
Coconut fatty acid diethanolamine 1. ,5
Oleyl triethoxy phosphate (BRIPHOS 03D) 1
Polyglycol-polyamine condensation
resin (POLYQUART H) [50% active] 1. ,5
Preservative, colouring matter, salt 0. ,58
Intermediate (33) 10
Perfume q.s.
Water 100
Example 26
% w/w
Sodium lauryl ether sulphate (2 EP)
[100% AD] 12
POLYMER JR400 2.5
BRIPHOS 03D 2.5
Intermediate (34) 15
Magnesium Sulphate 5
Perfume q.s.
Water to 100
Example 27
This Example also illustrates a lotion which is suitable for topical application to the scalp.
The lotion has the following formulation: % w/w
Intermediate (35) 5
minoxidil 1
propan-2-ol 10
ethanol 84
Example 28
This example illustrates a powder composition according to the invention which can be applied topically to the scalp.
% w/w
Chemically modified starch 5
Chemically modified cellulose
Boric acid 10
Zinc oxide 5
Intermediate (36) 3
Minoxidil 5
Perfume q.s.
Chalk 10
Talc to 100
Example 29 The following example illustrates a lotion according to the invention which can be applied topically to the scalp to prevent hair loss and stimulate hair regrowth. % w/w
Intermediate (37) 7
glucaro-l, 4-laσtone 2
ethanol 16
citric acid 1.05
water to 100 pH adjusted to 4.2 with sodium hydroxide Example 30
This example illustrates a shampoo which is suitable for topical application to hair in order to cleanse it, at the same time delivering a metabolic intermediate to the scalp to enhance hair growth or regrowth.
The shampoo had the following formulation: % w/w
Triethanolamine lauryl
sulphate 16.8
Coconut diethanolamide 3.0
Hydroxypropylmethyl- cellulose (1) 0.25
Corn syrup (80% solids) (2) 20.5
Dimethylpolysiloxane (3) 1.0
Cationic cellulose (4) 0.5
Ethyl alcohol (SDA 40) 9.0
Vinyl carboxy polymer (5) 0.75
Intermediate (38) 8
Perfume, colour, preservative q.s.
Water to 100 Acid or base to pH: 6.5
1 - Methocel E4M (Dow Chemical)
2 - 42 Dextrose equivalent (Staley 1300)
3 - 60,000 centistokes (Viscasil, GEC)
4 - Polymer JR 400
5 - Carbopol 941 (BF Goodrich)
Example 31 This example illustrates a shampoo in accordance with the invention. Firstly a pre-emulsion of polyisobutylene was made by mixing at room temperature the following ingredients in a Winkworth twin-Z-blade mixer (model MZ150). Pre-emulsion ingredient % w/w
Vistanex1 58
Alipal CO-4332 1.4
Water 40.6 (1) Polyisobutylene, approx molecular weight 60,000, ex Exxon. (2) Sodium alkyl phenyl polyethoxylene sulphate.
The pre-emulsion was then mixed, with stirring, with the additional ingredients of . the shampoo. to give a final composition as follows:
Ingredient % w/w
Pre-emulsion 1. 6
Sodium lauryl ether sulphate 2E0 14
Cocoamidopropylbetaine 2
Euperlan PK900(3) 10
Jaguar C13s(4) 0 . 1
Citrulline 4
Formalin 0 . 05
BY 22-026(5) 0. 4
NaCl 5
Perfume, colouring qs
Water to 100 (3) Mixture of triethylene glycol distearate and SLES 2EO, ex Henkel.
(4) Guar hydroxypropyl trimonium chloride, ex Meyhall. (5) Polydimethylsiloxane, 50% aqueous emulsion, ex Toray Silicone. Example 32
% w/w
SLES 2E0 16
Cocoamidopropyl betaine 2
Silicone emulsion(1) 4
Jaguar C13s 0. 1
Ornithine hydrochloride 5 . 5
Ethylene glycol distearate 5 . 0
Octopirox(2) 0. 5
Preservative, Colour, Perfume qs
Water to 100
(1) BY22-026 ex Toray Silicone Co Ltd comprising:
% w/w
Lauryl alcohol ethoxylate 2E0 2
Lauryl alcohol ethoxylate 21EO 2
Polydimethylsiloxane (60,000 cS) 50
Preservative qs
Water to 100
(2) Piroctone olamine ex Hoechst.
The shampoo is prepared using a simple hot process whereby all the ingredients except perfume are mixed at 70°C using a paddle stirrer. The mixture is then cooled slowly, and perfume added below 40°C.
Example 33
% w/w
Ammonium lauryl sulphate/
Ammonium lauryl ether sulphate 8
Cocodiethanolamide 3
Arginine hydrochloride 5.5
Ionol butyl hydroxytoluene (BHT) 0.05
BRIPHOS 03D(1) 1.05
Hydrolised silk protein 0.1 CARBOPOL 1342(2) 0.4
Polyethoxylated lanolin 0.3
JAGUAR C13s 0.3
TIMIRON MP-1005(3) 0.06
Triethanolamine 0.8
Silicone emulsion (50%)(4) 6
Perfume, Preservative qs
Water to 100 (1) A mixture of esters of phosphoric acid and the polyethylene glycol ether of oleyl alcohol.
(2) A copolymer of a carboxylic acid containing monomer and acrylic esters ex Goodrich.
(3) Titanium dioxide coated mica ex Merck.
(4) Silicone emulsion comprises 50% by weight silicone oil (60,000 cs), 4% by weight cetostearyl alcohol and 25% by weight SLES 2E0.
The ammonium lauryl sulphate/ammonium lauryl ether sulphate and the BHT were heated in the main vessel to 75°C to melt the BHT, with constant stirring.
CARBOPOL 1342 was dispersed with stirring in 50% of the water, and the resulting dispersion added to the main vessel.

Claims

CLAIMS:
1. Use for increasing, enhancing or maintaining
mammalian hair growth, following topical application, of a composition which comprises
(i) an effective amount of a metabolic intermediate of the urea cycle selected from the group consisting of the amino acids arginine, ornithine, citrulline and arginosuccinate, ester, alkyl, acyl, phosphatyl and peptide derivatives of said amino acids and salts and hydrosalts of said aminoacids and derivatives thereof, and
(ii) a cosmetically acceptable vehicle for said metabolic intermediate.
2. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of arginine, said derivatives of arginine, and salts and hydrosalts thereof.
3. Use according to claim 2 wherein the metabolic intermediate is selected from L-arginine and L-arginine hydrochloride.
4. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of ornithine, said derivatives of ornithine, and salts and hydrosalts thereof.
5. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of citrulline, said derivatives of citrulline, and salts and hydrosalts thereof.
6. Use according to claim 1 wherein the metabolic intermediate is selected from the group consisting of arginosuccinate, said derivatives of arginosuccinate, and salts and hydrosalts thereof.
7. Use according to claim 1, wherein the metabolic intermediate is chosen from: arginine hydrochloride
ornithine hydrochloride
sodium arginate
arginine phosphate, sodium salt
sodium arginosuccinate
potassium arginosuccinate
L-α-alanylarginine hydrochloride
L-cystinylornithine
L-methionylcitrulline
L-arginylarginine
L-ornithylcitrulline
L-glutaminylarginine
L-glutaminylcitrulline
L-tyrosinylarginine
L-arginylmethionine
L-ornithylmethionine
L-citrullylmethionine
L-arginylaspartate
L-arginylglutamate
L-arginylleucine acetate salt
L-arginyllysine acetate salt
L-arginylphenylalanine acetate salt
L-ornithylaspartate
methylarginine dihydrochloride
arginine ethyl ester dihydrochloride
ethylcitrulline
n-propylornithine
n-octylarginine
n-octylcitrulline
n-octylornithine
8. Use according to any one of claims 1 to 7 wherein the composition contains from 0.01 to 30% by weight of said metabolic intermediate.
9. Use according to any one of claims 1 to 8 wherein the composition contains not more than 4% by weight of
surfactant.
10. Use according to any one of claims 1 to 8 wherein the composition contains at least 4% by weight of surfactant and more than 5% by weight of said metabolic intermediate or derivative thereof.
11. Use according to any one of claims 1 to 10 by topical application to the bald or balding human scalp.
12. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of arginine, said derivatives of arginine, and salts and hydrosalts thereof.
13. A composition according to claim 12 wherein the metabolic intermediate is selected from L-arginine and L-arginine hydrochloride.
14. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of ornithine, said derivatives of ornithine, and salts and hydrosalts thereof.
15. A composition according to claim 11 wherein the metabolic intermediate is selected from the group
consisting of citrulline, said derivatives of citrulline, and salts and hydrosalts thereof.
16. A composition according to claim 11 wherein the metabolic intermediate is selected from the group consisting of arginosuccinate, said derivatives of arginosuccinate, and salts and hydrosalts thereof.
17. A composition according to claim 11, wherein the metabolic intermediate is chosen from: arginine hydrochloride
ornithine hydrochloride
sodium arginate
arginine phosphate, sodium salt sodium arginosuccinate
potassium arginosuccinate
L-α-alanylarginine hydrochloride
L-cystinylornithine
L-methionylcitrulline
L-arginylarginine
L-ornithylcitrulline
L-glutaminylarginine
L-glutaminylcitrul1ine
L-tyrosinylarginine
L-arginylmethionine
L-ornithylmethionine
L-citrullylmethionine
L-arginylaspartate
L-arginylglutamate
L-arginylleucine acetate salt
L-arginyllysine acetate salt
L-arginylphenylalanine acetate salt
L-ornithylaspartate
methylarginine dihydrochloride
arginine ethyl ester dihydrochloride
ethylcitrulline
n-propylornithine
n-octylarginine
n-octylcitrulline
n-octylornithine
18. A composition according to claim 11 in which the intermediate forms from 0.01 to 30% by weight of the composition.
PCT/GB1993/002210 1992-10-30 1993-10-27 Cosmetic composition WO1994009750A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002146348A CA2146348A1 (en) 1992-10-30 1993-10-27 Cosmetic composition
AU53426/94A AU5342694A (en) 1992-10-30 1993-10-27 Cosmetic composition
JP6510821A JPH08502509A (en) 1992-10-30 1993-10-27 Cosmetic composition
EP93923626A EP0666729A1 (en) 1992-10-30 1993-10-27 Cosmetic composition
KR1019950701705A KR950703926A (en) 1992-10-30 1995-04-29 Cosmetic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929222772A GB9222772D0 (en) 1992-10-30 1992-10-30 Cosmetic composition
GB9222772.7 1992-10-30

Publications (1)

Publication Number Publication Date
WO1994009750A1 true WO1994009750A1 (en) 1994-05-11

Family

ID=10724275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002210 WO1994009750A1 (en) 1992-10-30 1993-10-27 Cosmetic composition

Country Status (10)

Country Link
EP (1) EP0666729A1 (en)
JP (1) JPH08502509A (en)
KR (1) KR950703926A (en)
CN (1) CN1091952A (en)
AU (1) AU5342694A (en)
CA (1) CA2146348A1 (en)
GB (1) GB9222772D0 (en)
TW (1) TW262384B (en)
WO (1) WO1994009750A1 (en)
ZA (1) ZA938000B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747035A2 (en) * 1995-06-07 1996-12-11 Beiersdorf Aktiengesellschaft Composition for the treatment of dandruff and the treatment of hair
JPH09278630A (en) * 1996-02-15 1997-10-28 Kao Corp Hair cosmetic
WO1998007744A1 (en) * 1996-08-23 1998-02-26 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
EP0887067A2 (en) * 1997-06-25 1998-12-30 Kao Corporation Hair cosmetics
EP0956852A2 (en) * 1998-03-27 1999-11-17 Kao Corporation Skin external preparation
WO1999062462A2 (en) * 1998-06-01 1999-12-09 Unilever Plc Hair treatment compositions
FR2786693A1 (en) * 1998-12-04 2000-06-09 Dior Christian Parfums Topical slimming compositions containing a L-tyrosine-L-arginine synthetic peptide
WO2000047172A1 (en) * 1999-02-10 2000-08-17 Taisho Pharmaceutical Co., Ltd. Hair growth stimulants and method for screening substance having hair growth stimulating effect
EP1040815A1 (en) * 1999-04-01 2000-10-04 Friedrich Maindok Hair tonic comprising L-Arginine as active compound
US6509011B1 (en) 1999-07-23 2003-01-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of hair treatment using organic amino compounds
US6551361B1 (en) 1999-07-23 2003-04-22 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of hair treatment using organic amino compounds
FR2894142A1 (en) * 2005-12-05 2007-06-08 Oreal Use of a combination of niacinamide and tyrosine-arginine dipeptide or its derivatives e.g. to prevent and/or decrease cutaneous rednesses and/or swellings
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
EP2042157A1 (en) * 2006-06-08 2009-04-01 Ajinomoto Co., Inc. Hair growth composition
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US20120042894A1 (en) * 2009-03-20 2012-02-23 L'oreal Composition comprising the combination of madecassoside, of an arginine and of polysorbate
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US8858968B2 (en) 2005-12-05 2014-10-14 L'oreal Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist
WO2015062629A1 (en) 2013-10-29 2015-05-07 Cutech Srl Use of mono ornithine ketoglutarate (mokg)
US20150150771A1 (en) * 2012-06-19 2015-06-04 Debraj Shome Composition and method for an intradermal hair growth solution
US9050365B2 (en) 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
FR3022778A1 (en) * 2014-06-30 2016-01-01 Oreal USE OF A COMBINATION OF ORNITHINE AND CITRIC ACID TO LIMIT HAIR LOSS
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10463594B2 (en) 2012-10-17 2019-11-05 Ajinomoto Co., Inc. Cosmetic composition
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2160178B1 (en) * 2007-07-03 2014-04-23 Unilever PLC Hair styling composition
FR2929118B1 (en) * 2008-03-28 2010-05-07 Oreal USE OF THE ASSOCIATION OF MADECASSOSIDE AND / OR TERMINOLOSIDE AND ARGININE TO INDUCE AND / OR STIMULATE THE GROWTH OF HUMAN KERATIN FIBERS AND / OR BRAKE THEIR FALL
CN102526250A (en) * 2010-12-24 2012-07-04 漆又毛 Application of composition of amino acids and extracts in preparation of drugs with function of improving memory
JP6115086B2 (en) * 2012-11-13 2017-04-19 味の素株式会社 Cosmetic composition containing acetate of amino acid compound
CA3056156A1 (en) * 2016-03-24 2018-09-28 Cysal Gmbh Aspartyl-dipeptides for skin care and cosmetic use
CN107573404B (en) * 2017-09-22 2022-04-12 南京优科生物医药研究有限公司 Active salt of dipeptide compound of ornithine and aspartate and application thereof
JP7169623B2 (en) * 2018-02-14 2022-11-11 株式会社 リトル・サイエンティスト Cosmetic containing arginine ester
WO2021193820A1 (en) 2020-03-26 2021-09-30 味の素株式会社 Composition for promoting hair thickening, composition for sustaining growth phase in hair cycle and composition for promoting vegf production, composition for promoting transition from resting phase to growth phase in hair cycle and composition for promoting fgf7 production, and composition for promoting hair cycle normalization

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937362A (en) * 1958-07-24 1963-09-18 Margarete Ingrid Sendler Marbe Compositions for the care and growth of skin, hair and nails comprising magnesium compounds
DE3118882A1 (en) * 1981-05-13 1983-01-05 Rudolf V. Dr.rer.nat Dipl.-Chem. 5024 Pulheim Noronha Composition to counteract hair loss and promote hair growth
GB2140297A (en) * 1983-04-22 1984-11-28 Lion Corp Hair treatment compositions
JPS61151109A (en) * 1984-12-26 1986-07-09 Lion Corp Hair treatment composition
JPS61246130A (en) * 1985-04-24 1986-11-01 Japan Fine Chem Kk External agent for stimulation skin cell activity
EP0336265A2 (en) * 1988-03-25 1989-10-11 Ajinomoto Co., Inc. Hair cosmetic composition
FR2669224A1 (en) * 1990-11-15 1992-05-22 Contier Marcel Hair-care compositions intended, in particular, for neutralizing the lactic acid of the scalp, and method of cosmetic treatment of the scalp
JPH04308523A (en) * 1991-04-04 1992-10-30 Kanebo Ltd Hair-tonic cosmetic
DE4205931A1 (en) * 1992-02-20 1993-08-26 Maindok Friedrich Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth
EP0571198A1 (en) * 1992-05-20 1993-11-24 Unilever Plc Cosmetic composition containing hair-growth promoter

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937362A (en) * 1958-07-24 1963-09-18 Margarete Ingrid Sendler Marbe Compositions for the care and growth of skin, hair and nails comprising magnesium compounds
DE3118882A1 (en) * 1981-05-13 1983-01-05 Rudolf V. Dr.rer.nat Dipl.-Chem. 5024 Pulheim Noronha Composition to counteract hair loss and promote hair growth
GB2140297A (en) * 1983-04-22 1984-11-28 Lion Corp Hair treatment compositions
JPS61151109A (en) * 1984-12-26 1986-07-09 Lion Corp Hair treatment composition
JPS61246130A (en) * 1985-04-24 1986-11-01 Japan Fine Chem Kk External agent for stimulation skin cell activity
EP0336265A2 (en) * 1988-03-25 1989-10-11 Ajinomoto Co., Inc. Hair cosmetic composition
FR2669224A1 (en) * 1990-11-15 1992-05-22 Contier Marcel Hair-care compositions intended, in particular, for neutralizing the lactic acid of the scalp, and method of cosmetic treatment of the scalp
JPH04308523A (en) * 1991-04-04 1992-10-30 Kanebo Ltd Hair-tonic cosmetic
DE4205931A1 (en) * 1992-02-20 1993-08-26 Maindok Friedrich Use of infusion soln. of electrolyte concentrate of arginine hydrochloride - prevents hair fallout and promotes hair growth
EP0571198A1 (en) * 1992-05-20 1993-11-24 Unilever Plc Cosmetic composition containing hair-growth promoter

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8634, Derwent World Patents Index; AN 86-221280 *
DATABASE WPI Week 8650, Derwent World Patents Index; AN 86-329438 *
DATABASE WPI Week 9250, Derwent World Patents Index; AN 92-411554 *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0747035A2 (en) * 1995-06-07 1996-12-11 Beiersdorf Aktiengesellschaft Composition for the treatment of dandruff and the treatment of hair
EP0747035A3 (en) * 1995-06-07 1998-03-04 Beiersdorf Aktiengesellschaft Composition for the treatment of dandruff and the treatment of hair
JPH09278630A (en) * 1996-02-15 1997-10-28 Kao Corp Hair cosmetic
WO1998007744A1 (en) * 1996-08-23 1998-02-26 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
US6372717B1 (en) * 1996-08-23 2002-04-16 Sederma S.A. Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions
EP0887067A2 (en) * 1997-06-25 1998-12-30 Kao Corporation Hair cosmetics
EP0887067A3 (en) * 1997-06-25 2003-07-30 Kao Corporation Hair cosmetics
US8603519B2 (en) 1997-09-17 2013-12-10 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
EP0956852A2 (en) * 1998-03-27 1999-11-17 Kao Corporation Skin external preparation
EP0956852A3 (en) * 1998-03-27 2005-05-18 Kao Corporation Skin external preparation
US6432420B2 (en) 1998-06-01 2002-08-13 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Hair treatment compositions
WO1999062462A3 (en) * 1998-06-01 2000-03-02 Unilever Plc Hair treatment compositions
WO1999062462A2 (en) * 1998-06-01 1999-12-09 Unilever Plc Hair treatment compositions
FR2786693A1 (en) * 1998-12-04 2000-06-09 Dior Christian Parfums Topical slimming compositions containing a L-tyrosine-L-arginine synthetic peptide
WO2000047172A1 (en) * 1999-02-10 2000-08-17 Taisho Pharmaceutical Co., Ltd. Hair growth stimulants and method for screening substance having hair growth stimulating effect
EP1040815A1 (en) * 1999-04-01 2000-10-04 Friedrich Maindok Hair tonic comprising L-Arginine as active compound
US6509011B1 (en) 1999-07-23 2003-01-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of hair treatment using organic amino compounds
US6551361B1 (en) 1999-07-23 2003-04-22 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of hair treatment using organic amino compounds
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9050365B2 (en) 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
FR2894142A1 (en) * 2005-12-05 2007-06-08 Oreal Use of a combination of niacinamide and tyrosine-arginine dipeptide or its derivatives e.g. to prevent and/or decrease cutaneous rednesses and/or swellings
EP1795181A1 (en) * 2005-12-05 2007-06-13 L'Oréal Cosmetic and pharmaceutical uses of the dipeptide tyrosine-arginine in combination with niacinamide as substance P antagonist
US8858968B2 (en) 2005-12-05 2014-10-14 L'oreal Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist
EP2042157A4 (en) * 2006-06-08 2013-12-04 Ajinomoto Kk Hair growth composition
EP2042157A1 (en) * 2006-06-08 2009-04-01 Ajinomoto Co., Inc. Hair growth composition
WO2009030453A1 (en) * 2007-09-07 2009-03-12 Cutech Srl. Compositions comprising ornithine ketoglutarate (okg)
US8466112B2 (en) 2007-09-07 2013-06-18 Cutech S.R.L. Compositions comprising Ornithine Ketoglutarate (OKG)
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
US20120042894A1 (en) * 2009-03-20 2012-02-23 L'oreal Composition comprising the combination of madecassoside, of an arginine and of polysorbate
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10898489B2 (en) 2009-06-24 2021-01-26 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US9155701B2 (en) 2009-06-24 2015-10-13 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US9161915B2 (en) 2009-06-24 2015-10-20 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US10682357B2 (en) 2009-06-24 2020-06-16 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9737543B2 (en) 2009-06-24 2017-08-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US9457092B2 (en) 2009-06-24 2016-10-04 Strategic Science & Technologies, Llc Delivery of ibuprofen and other compounds
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9492458B2 (en) 2009-06-24 2016-11-15 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10172865B2 (en) 2009-06-24 2019-01-08 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9675619B2 (en) 2009-06-24 2017-06-13 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
US9833456B2 (en) 2010-12-29 2017-12-05 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9498482B2 (en) 2010-12-29 2016-11-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9700504B2 (en) * 2012-06-19 2017-07-11 Debraj Shome Composition and method for an intradermal hair growth solution
US20150150771A1 (en) * 2012-06-19 2015-06-04 Debraj Shome Composition and method for an intradermal hair growth solution
US10463594B2 (en) 2012-10-17 2019-11-05 Ajinomoto Co., Inc. Cosmetic composition
WO2015062629A1 (en) 2013-10-29 2015-05-07 Cutech Srl Use of mono ornithine ketoglutarate (mokg)
FR3022778A1 (en) * 2014-06-30 2016-01-01 Oreal USE OF A COMBINATION OF ORNITHINE AND CITRIC ACID TO LIMIT HAIR LOSS

Also Published As

Publication number Publication date
CN1091952A (en) 1994-09-14
JPH08502509A (en) 1996-03-19
AU5342694A (en) 1994-05-24
ZA938000B (en) 1995-04-28
EP0666729A1 (en) 1995-08-16
CA2146348A1 (en) 1994-05-11
KR950703926A (en) 1995-11-17
TW262384B (en) 1995-11-11
GB9222772D0 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
WO1994009750A1 (en) Cosmetic composition
US5559092A (en) Cosmetic composition
US8632759B2 (en) Hair restorer
CA2077144C (en) Cosmetic composition
US5300284A (en) Glycosaminoglycanase inhibitor andethane diol composition for maintenance of hair growth
JP2001517688A (en) Use of ellagic acid and its derivatives in cosmetics and dermatology
JPH0363213A (en) Cosmetic compound
US6184252B1 (en) 2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss
JPH0445486B2 (en)
CA2096506C (en) Cosmetic composition
EP0580409A2 (en) Cosmetic composition containing DOPA derivatives
KR970001642B1 (en) Cosmetic composition
JP3644809B2 (en) External preparation for head
CA2016351C (en) Cosmetic composition
JPH03112912A (en) Cosmetic composition
JP3505003B2 (en) External preparation
JP2002037716A (en) Kaurenes-containing composition, hair-growing agent and skin care agent
JP3496896B2 (en) Hair restorer and hair cosmetic
EP0866684A1 (en) Cosmetic hair treatment method
FR2991873A1 (en) COMPOSITION COMPRISING A DYARBOXYLIC PYRIDINE ACID ESTER AND A GLUCOSE ESTER AND FATTY ACID ESTER, PROCESS AND USE
JP2001288042A (en) Composition for scalp and hair
JPH09227328A (en) Cosmetics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993923626

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2146348

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993923626

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1993923626

Country of ref document: EP